Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14357531 | 1.00 | VDR (0.56) | VDRCYP24A1 | |
| SCHEMBL14617409 | 0.95 | VDR (0.53) | VDRCYP24A1 | |
| SCHEMBL9010583 | 0.95 | VDR (0.57) | VDRCYP24A1 | |
| SCHEMBL9010530 | 0.93 | VDR (0.60) | VDRCYP24A1 | |
| SCHEMBL10820227 | 0.91 | VDR (0.54) | VDR | |
| SCHEMBL14489228 | 0.91 | VDR (0.54) | VDR | |
| SCHEMBL14112577 | 0.91 | VDR (0.54) | VDR | |
| SCHEMBL13641657 | 0.91 | VDR (0.54) | VDRCYP24A1 | |
| SCHEMBL12634985 | 0.91 | VDR (0.54) | VDRCYP24A1 | |
| SCHEMBL13158137 | 0.91 | VDR (0.54) | VDRCYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440647-B2 | 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-05-14 | — | — | US | disclosed |
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-7713952-B2 | 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-20070249567-A1 | 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-7244719-B2 | 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7241749-B2 | 2α-Methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249567-A1 | 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses | CYP27B1, CYP24A1, VDR | VDR 3/4885CYP24A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.